Abstract | BACKGROUND: High-dose chemotherapy (HD-CT) is able to circumvent platinum resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach. MATERIALS AND METHODS: RESULTS: From March 1998 to September 2001 (median follow-up, 31.8 months), 45 patients (median age, 28 years) were enrolled in this phase II study. Twenty-two patients received the complete course. Twenty-five patients died from progression and five from toxicity. The overall response rate was 37.7%, including an 8.9% complete response rate. The median overall survival was 11.8 months. The 3-year survival and progression-free survival rate was 23.5%. The 'Beyer' prognostic score predicted the outcome after HD-CT. CONCLUSION: Although our results warrant further studies on HD-CT in relapsed poor prognosis GCTs, patients with a Beyer score >2 did not benefit from this approach and should not be enrolled in HD-CT trials. Better selection criteria have to be fulfilled in forthcoming studies.
|
Authors | J-P Lotz, B Bui, F Gomez, C Théodore, A Caty, K Fizazi, G Gravis, R Delva, J Peny, P Viens, B Duclos, T De Revel, H Curé, J Gligorov, S Guillemaut, C Ségura, S Provent, J-P Droz, S Culine, P Biron, Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG) |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 16
Issue 3
Pg. 411-8
(Mar 2005)
ISSN: 0923-7534 [Print] England |
PMID | 15659420
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Epirubicin
- Etoposide
- Carboplatin
- Paclitaxel
- Ifosfamide
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Carboplatin
(administration & dosage)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Epirubicin
(administration & dosage)
- Etoposide
(administration & dosage)
- Humans
- Ifosfamide
(administration & dosage)
- Infusions, Intravenous
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Neoplasms, Germ Cell and Embryonal
(drug therapy, pathology)
- Paclitaxel
(administration & dosage)
- Prognosis
- Stem Cell Transplantation
- Testicular Neoplasms
(drug therapy, pathology)
- Transplantation, Autologous
- Treatment Outcome
|